Contract Negotiation Lead - Specialty GPO's, Large Dialysis Organizations, Oncology Aggregators, Oncology Centers and Mass Vaccinators for Moderna's Respiratory Vaccines.

Provide US coverage, coding and payment expertise to support the Lantheus Holdings portfolio regional commercial and medical teams. Responsible for implementation of brand reimbursement strategies, achieve and maintain positive payer coverage policies for key products, and educate key customers on payer coverage, coding and payment policies affecting the Lantheus Holding portfolio.

Assist with the commercial promotion and utilization of Ardelyx product lines to select dialysis provider organizations. Primary responsibility to assess and diagnose the current business environment in each key account in relation to Ardelyx products and strategies, and to plan actions required for success in these accounts. Additionally, responsible for coordinating field sales force promotion and activities within their assigned provider accounts. Primary customers include executive management, mid-level management, and key clinical decision-makers of dialysis organizations.

Facilitate Healthcare Practitioner offices in obtaining Specialty Therapy for CKD patients suffering from Metabolic Acidosis. Ensure optimal access, effective Prior Authorization pull-through, Payer process and Policy, understanding of HUB services including Patient Assistance Programs. • Develop and Execute Launch Strategy in Nephrology Space.• Support company and regional reimbursement strategy for Tricida product portfolio within various payer segments while navigating across multiple internal stakeholders, including Hub’s, and Sales Teams. • Dedicated and focused while providing customer-facing support for prior authorizations, payer formularies, step edit policy, appeals, peer to peer reviews, utilization criteria, etc.

Retained and promoted following merger of Genzyme with Sanofi as 1 of 5 chosen to pioneer newly formed National Account Team. Developed relationships with Key Thought Leaders and Dialysis Clinical and Operational Leadership to grow market share for Renvela, Hectorol IV, and Synvisc in AZ, NV, CA, UT, ID, OR, WA, CO, TX, and NM. Leveraged strategic relationships with key decision makers to drive formulary additions, market share growth, positive patient outcomes, and KOL / Speaker development. Collaborated with medical / clinical resources and MSLs in development of patient-outcome-based programs. Trained new sales reps. Educated Reimbursement Specialists on buy & bill procedures and methods to minimize denials. Selected accomplishments: ✦ Opened up limited access to physicians for sales representatives from 3 to 20 Arizona Dialysis Clinics through relationship building techniques with Key Opinion Leaders and Operational / Clinical Leadership.✦ Identified, recruited, and developed trusted relationships with 3 Nephrology Key Opinion Leaders in NV, AZ, and CA (previously non-existent). ✦ Improved overall market share for Renvela 12% and 14% in the Low Income Subsidy / Medicare Part D population. ✦ Led creation of access strategy, contract development, and reimbursement program for Synvisc.✦ Signed 22 contracts (15-contract goal) and stabilized market share at 49% despite competitive strategy disadvantages for Synvisc.✦ IDN C-Suite Strategic Relationship Development at Christus Health, Banner Health, Univ Of CA✦ Catapulted market share 97% by initiating a Hectorol IV 1500-patient outcome improvement pilot program project in Las Vegas Market to rectify contractual disadvantage against competitors. ✦ Devised and incorporated a NAM Preceptorship program to fill future positions with quality candidates. Three Preceptors' promoted to positions of greater accountability. ✦ Honored with multiple Peer Leadership Awards in 2010, 2013, 2014, and 2015.

Retained following acquisition of Bone Care by Genzyme, charged with promoting Hectorol injectable and Renvela oral products to specialists, and exceeding sales quotas in the New Mexico and Arizona territory. Formulated and implemented business plan which analyzed opportunities and detailed relevant activities. Selected accomplishments: ✦ Outperformed goal for Renvela 117% (ranked #8 of 92 nationally) and Hectorol IV 106% (#12 of 92 nationally) by focusing on high prescribing physicians and influential decision makers within the territory.✦ Earned reputation as a subject-matter expert in Buy & Bill reimbursement and insurance policy guidelines with Low Income Subsidy, Medicare Part D, Medicaid, and commercial payers to elevate product sales.

Initially hired as a Dialysis Sales Specialist; promoted to Regional Account Manager to utilize pharmaceutical company background to identify and develop relationships with Key Opinion Leaders to serve as product advocates, as well as formulate business plans, and exceed sales objectives for Hectorol IV and oral formulations. Communicated compliant clinical information to key prescribers. Presented accurate Buy & Bill information to physicians and office staff to minimize denials and secure reimbursement.Selected accomplishments: ✦ Grew sales of Hectorol IV from $18,000 to $526,000, increased market share from 9% to 55%, and converted 2000 dialysis patients to Hectorol in a two-year timeframe by meeting with key decision makers and medical directors and gaining commitment to switch patients based upon economic and clinical advantages.✦ Identified, recruited, and developed 4 Nephrologists in Arizona to serve as speakers for Hectorol where no previous KOLs had been identified.✦ Ranked #4 out of 30 nationally for exceptional sales accomplishments, which resulted in earning the Champions Club award in 2004. ✦ Collaborated with key dialysis providers and physicians to promote awareness and screening as a member of the Arizona Kidney Foundation.

Recruited during company expansion of the nephrology sales team in preparation for the launch of the new buy & bill injectable product, Aranesp while maintaining / exceeding sales for Epogen. Developed and implemented solid business plans to target key physicians. Educated physicians and staff on J-Code documentation and methods to code procedures and correctly bill to ensure reimbursement. Collaborated with anemia outcome managers to optimize patient outcomes. Identified and formed relationships with Key Opinion / Thought Leaders in the Nephrology disease state.Selected accomplishments: ✦ Pinpointed, developed trusted relationships with, and facilitated training of Key Opinion Leaders in Arizona (none prior) in collaboration with Amgen Medical Team, which resulted in 2 Nephrologists serving as speakers and product advocates for the disease state.✦ Instrumental in improving anemia patient outcomes from 55% to 76% on average (most improved in 2001) in the New Mexico market by developing working relationships with Anemia Managers in targeted dialysis facilities, providing training and education to drive patient outcomes, and creating / initiating anemia treatment protocols in targeted facilities, monitoring patient outcomes in monthly patient chart reviews, and recommending treatment adjustments.✦ Ranked #10 / 90 nationally (2001) and #9 / 92 nationally (2002) for educating key stake holders in dialysis centers, initiating patient conversions, and training staff on buy & bill procedures in New Mexico and Arizona.✦ Recognized with President's Club honors for exceptional sales achievement in 2001 and 2002. ✦ Served as the Amgen Representative at Arizona Kidney Foundation meetings.